<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728440</url>
  </required_header>
  <id_info>
    <org_study_id>FB03232016</org_study_id>
    <nct_id>NCT02728440</nct_id>
  </id_info>
  <brief_title>Effects of Gonadotropin Replacement Therapy on Metabolic Parameters in Patients With Hypogonadism</brief_title>
  <official_title>Lipid Profile and Oxidative Stress Parameters of Patients With Idiopathic Hypogonadotropic Hypogonadism and the Change of These Parameters With Gonadotropin Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gulhane School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gulhane School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of gonadotrophin replacement therapy Lipid Profile and Oxidative Stress Parameters of
      Patients with Idiopathic Hypogonadotropic Hypogonadism
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 male patients diagnosed with IHH and a control group of 20 healthy cases with similar age
      and BMI were included in the study. The levels of advanced oxidation protein products (AOPP),
      thiol, malondialdehyde (MDA), nitric oxide (NO) and 8-hydroxydeoxyguanosine (8-OHdG) and the
      levels of triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL-K), low
      density lipoprotein (LDL-K), Apolipoprotein A1 (ApoA1) and Apolipoprotein B100 (ApoB100) were
      measured before and after gonadotrophin therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>oxidative stress after hCG and HMG treatment</measure>
    <time_frame>2010-2012</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL levels after hCG treatment</measure>
    <time_frame>2010-2012</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>total cholesterole levels after hCG treatment</measure>
    <time_frame>2010-2012</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Idiopathic Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Hypogonadotropic hypogonadism patients</arm_group_label>
    <description>30 patients with idiopathic hypogonadotrophic hypogonadism</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin, human menopausal gonadotropin</intervention_name>
    <description>drug for the treatment of male hypogonadism</description>
    <arm_group_label>Hypogonadotropic hypogonadism patients</arm_group_label>
    <other_name>Pregnyl ® Organon hCG 1500 IU</other_name>
    <other_name>Merional ® ARIS 75 IU</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Idiopathic Hypogonadotropic Hypogonadism and healthy control group
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Serum testosterone concentration &lt; 300ng/dL Absence of a pituitary or hypothalamic mass
        lesions, Presence of gonadotropin response to GnRH, -

        Exclusion Criteria:

        diabetes mellitus, arterial hypertension other hormone deficiencies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gulhane School of Medicine</investigator_affiliation>
    <investigator_full_name>Aydogan Aydogdu</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

